Skip to content
Disclosery

EXANE DERIVATIVES: SHAK position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on SHAK, newest first. How the timeline and the estimate are built.

EXANE DERIVATIVES held 0 SHAK shares at 2021-12-31 per its 13F-HR filed 2022-01-28.

the latest 13F is the newest step

  1. period ended2021-12-31
    13F 0 shares
    Change vs previous 13F -438 shares

    13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

    Exited: the 13F for this period no longer lists the position.

  2. period ended2021-09-30
    13F 438 shares
    Change vs previous 13F -93 shares

    0.01% of the 13F portfolio, value $34,364.

    13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2021-06-30
    13F 531 shares
    Change vs previous 13F -2,092 shares

    0.01% of the 13F portfolio, value $54,187.

    13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2021-03-31
    13F 2,623 shares
    Change vs previous 13F -231 shares

    0.09% of the 13F portfolio, value $295,783.

    13F-HR 0001623883-21-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2020-12-31
    13F 2,854 shares
    Change vs previous 13F +1,614 shares

    0.07% of the 13F portfolio, value $241,951.

    13F-HR 0001623883-21-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  6. period ended2020-09-30
    13F/A 1,240 shares
    Change vs previous 13F not available

    0.03% of the 13F portfolio, value $79,951.

    13F-HR/A 0001623883-20-000010 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).